Meesmann corneal dystrophy
Other Names for this Disease
- Corneal dystrophy, juvenile epithelial of Meesmann
- Juvenile hereditary epithelial dystrophy
- Juvenile hereditary epithelial dystrophy of Meesmann
- Meesman dystrophy
On this page
Treatment is usually not needed unless a person is experiencing symptoms. Most people only need lubricating eye drops. If symptoms are more severe, therapeutic contact lenses or cycloplegic eye drops may be used for severe sensitivity to light (photophobia). Hypertonic saline may be given if symptoms get worse when a person wakes up. Surgical procedures are sometimes tried when these treatments do not help, and may include epithelial debridement, or keratectomy. There is a high risk of recurrence with these procedures. Researchers are also evaluating a form of gene therapy called RNA interference (RNAi) which is also called therapeutic siRNA. This therapy may be able to silence the mutated gene that causes Meesman corneal dystrophy.
Last updated: 1/2/2014
- Corneal Dystrophies. In: Traboulsi EI. Genetic Diseases of the Eye. New York, NY: Oxford University Press; 1998;
- Liao H, Irvine AD, Macewen CJ, Weed KH, Porter L, Corden LD, Gibson AB, Moore JE, Smith FJ, McLean WH, Moore CB. Development of Allele-Specific Therapeutic siRNA in Meesmann Epithelial Corneal Dystrophy. PLoS One. 2011; 6(12):e28582. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236202/. Accessed 1/2/2014.
- Jalbert, I, Stapleton, F. Management of Symptomatic Meesmann Dystrophy. Optometry and Vision Science. October 2009; 86(10):E1202-E1206. http://www.ncbi.nlm.nih.gov/pubmed/19741557. Accessed 1/2/2014.
- ClinicalTrials.gov lists trials that are studying or have studied Meesmann corneal dystrophy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
- The U.S. National Institutes of Health, through the National Library of Medicine, developed ClinicalTrials.gov to provide patients, family members, and members of the public with current information on clinical research studies. There is a study titled Screening Study for the Evaluation and Diagnosis of Potential Research Participants which may be of interest to you. To find this trial, click on the link above.
- Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.